Johnson & Johnson will excise less profitable lines and markets within its Depuy Synthes orthopedics business over the next two years, management revealed in its quarterly investor call on Oct. 16. Paring its products and related pursuits could cost as much as $800 million by the end of 2025, J&J Chief Financial Officer Joe Wolk said.
Johnson & Johnson has been looking to make a big splash in robotics. Now, its Depuy Synthes unit has made progress on this front, gaining U.S. FDA clearance for the Velys robotic-assisted solution designed for use with the Attune total knee system. The solution aims to help simplify surgeons’ existing workflow around total knee replacement.
Johnson & Johnson (J&J) said it will deliver its differentiated value propositions for patients Thursday as it provided details on its Ottava platform during its Virtual Medical Devices Update. Analysts appear to have left the meeting with a good impression. “We came away impressed with JNJ's digital surgery vision & holistic approach,” wrote Cowen’s Josh Jennings.
